Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
-
Published:2022-07
Issue:
Volume:170
Page:64-72
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Rossini Daniele, Germani Marco M., Lonardi SaraORCID, Pietrantonio Filippo, Dell'Aquila Emanuela, Borelli Beatrice, Allegrini Giacomo, Maddalena Giulia, Randon Giovanni, Marmorino Federica, Zaniboni Alberto, Buonadonna Angela, Boccaccino AlessandraORCID, Conca VeronicaORCID, Antoniotti Carlotta, Passardi Alessandro, Masi GianlucaORCID, Cremolini Chiara
Subject
Cancer Research,Oncology
Reference38 articles.
1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016 2. Colon cancer, version 2.2021, NCCN clinical practice guidelines in Oncology;Benson;J Natl Compr Cancer Netw,2021 3. First-line chemotherapy for mCRC—a review and evidence-based algorithm;Cremolini;Nat Rev Clin Oncol,2015 4. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014 5. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|